{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Elahere"},{"type":"CodeName","name":"IMGN853"},{"type":"Synonym","name":"M9346A-sulfo-SPDB-DM4"},{"type":"CASRegistryName","name":"1453084-37-1"},{"type":"Synonym","name":"mirvetuximab Soravtansine-gynx"},{"type":"CodeName","name":"TAK-853"},{"type":"CodeName","name":"TAK853"},{"type":"CodeName","name":"TAK 853"}],"definition":{"html":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.","text":"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/mirvetuximab-soravtansine-gynx","text":"Mirvetuximab Soravtansine-gynx"},"nciConceptId":"C102566","nciConceptName":"Mirvetuximab Soravtansine","termId":734941,"name":"mirvetuximab soravtansine","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mirvetuximab-soravtansine"}],"links":null}